« Previous | All Messages |  APNS Message Board Home | recommend post |  Ignore Poster

APNS News CORRECTING and REPLACING Dutton Associates Announces Investment Opinion: Applied NeuroSolutions Strong Speculative Buy Rating Reiterated In Update Coverage By Dutton Associates

EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Headline of release should read: Dutton Associates Announces Investment Opinion: Applied NeuroSolutions Strong Speculative Buy Rating Reiterated In Update Coverage By Dutton Associates. Also, in the first graph, the first sentence should read: Dutton Associates updates its coverage of Applied NeuroSolutions (OTCBB:APNS), maintaining a Strong Speculative Buy rating and a $1.00 target price (sted $18.00 target price.)

The corrected release reads:

DUTTON ASSOCIATES ANNOUNCES INVESTMENT OPINION: APPLIED NEUROSOLUTIONS STRONG SPECULATIVE BUY RATING REITERATED IN UPDATE COVERAGE BY DUTTON ASSOCIATES

Dutton Associates updates its coverage of Applied NeuroSolutions (OTCBB:APNS), maintaining a Strong Speculative Buy rating and a $1.00 target price. The nine-page report by Dutton senior analyst Denise T. Resnik, M.S., is available at www.jmdutton.com, as well as from First Call, Bloomberg, Zacks, Reuters, Knobias and other leading financial portals.

Applied NeuroSolutions is attracting an increasing level of interest within the healthcare and financial fields, which we believe results from its promising intellectual property in the understanding of Alzheimer’s disease. The recently-announced agreement with Eli Lilly and Company (NYSE:LLY), discussed in our report, will position Applied NeuroSolutions to be able to further validate their science and to continue their work in developing novel diagnostic and therapeutic products in the critical area of Alzheimer’s disease. While we believe that there is certainly a level of risk in any development-stage biopharmaceutical company, Applied NeuroSolutions now seems poised to continue its research and development in an area of great upside potential. Accordingly, we recently upgraded our recommendation of the stock to Strong Speculative Buy from Speculative Buy, which was based on the Company’s science but tempered by the Company’s previous financial uncertainties.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $33,000 from the Company for 4 Research Reports with coverage commencing on 6/28/2008. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.